Compare PBHC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | THAR |
|---|---|---|
| Founded | 1859 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 90.8M |
| IPO Year | N/A | 2022 |
| Metric | PBHC | THAR |
|---|---|---|
| Price | $14.34 | $2.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 558.3K |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $44,154,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 24.40 | N/A |
| 52 Week Low | $13.35 | $0.95 |
| 52 Week High | $17.50 | $9.08 |
| Indicator | PBHC | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 51.18 |
| Support Level | $13.96 | $2.76 |
| Resistance Level | $14.38 | $3.09 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 86.08 | 15.00 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.